Morgan Stanley Upgrades BioNTech to Overweight, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has upgraded BioNTech (NASDAQ:BNTX) from Equal-Weight to Overweight and increased the price target from $93 to $145, indicating a positive outlook for the company's stock.
September 24, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has upgraded BioNTech to Overweight and raised the price target to $145, suggesting a positive short-term outlook for the stock.
The upgrade from Equal-Weight to Overweight by Morgan Stanley, along with a significant increase in the price target, indicates strong confidence in BioNTech's future performance. This is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100